Landiolol Hydrochloride is an ultra-short-acting beta-adrenergic antagonist primarily indicated for the management of intraoperative and postoperative cardiac arrhythmias, as well as tachycardia during… Read more
Landiolol Hydrochloride is an ultra-short-acting beta-adrenergic antagonist primarily indicated for the management of intraoperative and postoperative cardiac arrhythmias, as well as tachycardia during anesthesia. Because of its rapid onset and short duration of action, precise monitoring of the active pharmaceutical ingredient is essential in clinical and manufacturing environments. This category offers high-quality reference standards, including both pharmacopeial and non-pharmacopeial impurities, alongside stable isotope-labelled compounds. These reference materials are critical for laboratories performing impurity profiling, method validation, and routine quality control testing to ensure the consistency and safety of drug products. By utilizing these characterized standards, analysts can accurately identify degradation products, verify assay specificity, and support regulatory compliance throughout the pharmaceutical development lifecycle of this potent cardiovascular agent.